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Abstract: The aim was to explore the relation of human milk lutein; choline; and docosahexaenoic
acid (DHA) with recognition memory abilities of six-month-olds. Milk samples obtained
three to four months postpartum were analyzed for fatty acids, lutein, and choline. At six
months, participants were invited to an electrophysiology session. Recognition memory was
tested with a 70–30 oddball paradigm in a high-density 128-lead event-related potential (ERP)
paradigm. Complete data were available for 55 participants. Data were averaged at six groupings
(Frontal Right; Frontal Central; Frontal Left; Central; Midline; and Parietal) for latency to peak, peak
amplitude, and mean amplitude. Difference scores were calculated as familiar minus novel. Final
regression models revealed the lutein X free choline interaction was significant for the difference
in latency scores at frontal and central areas (p < 0.05 and p < 0.001; respectively). Higher choline
levels with higher lutein levels were related to better recognition memory. The DHA X free choline
interaction was also significant for the difference in latency scores at frontal, central, and midline
areas (p < 0.01; p < 0.001; p < 0.05 respectively). Higher choline with higher DHA was related to better
recognition memory. Interactions between human milk nutrients appear important in predicting
infant cognition, and there may be a benefit to specific nutrient combinations.
Keywords: breastmilk; DHA; choline; lutein; recognition memory; infant cognition; synergy;
electrophysiology; nutrition
1. Introduction
On a molecular level, nutrients appear to be integral to brain development and subsequent
cognition. Nonetheless, empirical evidence of a relation between nutrient intake and brain function
has been elusive. The difficulty in documenting nutritional effects on brain could be because most
research is focused on a single nutrient. Nutrients do not exist in isolation nor is consumption limited
to one type of food. Thus, nutrients may work synergistically in the brain. We tested the effects of
choline, docosahexaenoic acid (DHA), and lutein on recognition memory in six-month-old infants
using an electrophysiology paradigm known as event-related potentials (ERP).
Early choline status has been shown to be important for later adult memory in animal models [1].
Given the distal nature of the effects, it is not surprising that when early choline was tested in relation
to early cognition, the results were mixed with some researchers not finding definitive effects [2,3] and
others reporting positive effects [4]. Indeed, in data from Project Viva, no relation was found between
maternal intake of choline and cognition at three years [5], but associations emerged at seven years [6].
Others have found effects of concurrent choline on cognition in adults [7]. Evidence from animal
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models indicates that the integrity of the hippocampus and by extension, visuospatial memory, is
related to choline intake. Importantly, choline is co-localized with DHA in the brain and liver.
Fatty acid researchers also have found mixed results when supplementing infant diets with DHA;
fewer than 40% of trials evidence an effect on cognition when infants are born full-term [8], although
researchers working with infants born pre-term have found more consistent results [9,10] albeit
short-term [11]. Nonetheless, DHA is prevalent in the structures that underlie cognitive abilities,
specifically, the eye, the hippocampus, and the frontal brain areas. There is evidence to suggest that
DHA supplementation in infancy improves problem-solving [12] and visual acuity [13] in infancy
and hippocampal-based cognitive outcomes in toddlerhood [14]. Suggestively, researchers have
shown the importance of controlling for DHA when studying environmental contaminants, as DHA
is protective against the negative effects of toxins, such as mercury, on the brain and subsequent
cognition [15,16].
In the aging primate eye, lutein has been associated with reduced damage to the macula from
blue light [17], and in adults there is an association between lutein and cognition [18,19]. In the
developing eye, macular pigment optical density increases as serum lutein increases [20]. Lutein
is deposited into the macula (which is the most immature structure of the eye at birth) concurrent
with the development of visual acuity, which occurs across the first year of life. However, it is not
known if the two are related: very little work has been done on the effects of lutein early on. Animal
models suggest that lutein is important to the development of the eye [21] as is DHA. In one study
of the association between plasma lutein and cognition in young children (five to six years old),
no relation was found [22]. However, the design of the study included lutein as a single nutrient,
as is common practice.
As noted, nutrients most likely work together to exact effects, and small hints at synergistic
effects have emerged. In tests of delayed recall, Johnson [19] showed that delayed recall was better
in elderly participants who were supplemented with DHA and lutein, relative to those who were
supplemented with DHA or lutein singularly. In the liver, choline is necessary for the release
of DHA stores into the bloodstream. Moreover, DHA and lutein are transported to the brain by
phospholipid-rich lipoproteins [23]. For these reasons, we hypothesize that the effects of nutrition on
recognition memory will be greater based on two nutrients, as opposed to a single nutrient.
2. Experimental Section
2.1. Participants
One hundred five exclusively breastfed 6-month-old infants participated in the context of a
larger study conducted in the southeastern United States between 2010 and 2012. All but two of the
105 infants (98.1%) were 100% breastfed; the two others were supplemented with no more than
10% formula. The mothers were under 45 years of age, had unremarkable pregnancies, and gave
birth to healthy, single infants at term. The sample was 82% Caucasian and 49% male. The data
presented here are a secondary analysis.
Of those who came in for the ERP session, 67 participants (mean age 6.1 months (mo), sd = 0.9)
provided good data; 2 participants did not tolerate the net; 3 sessions had no data due to technical
difficulties; 6 sessions were stopped due to fussing and crying; and 24 participants did not provide
sufficient clean data (defined as a minimum of 10 artifact free segments for each condition). This
dropout rate is within that typically seen in infant ERP studies [24,25]. The analyses include those
from the larger study who had clean ERP data as well as milk choline, lutein, and DHA data (n = 55).
2.2. Study Design
The participants were invited to the laboratory where the study was explained to them in
detail. All gave written informed consent for themselves and their infants in accordance with the
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Institutional Review Board (09-1869; current approval date 31 August 2015). This research study is
registered at ClinicalTrials.gov (NCT01942434).
2.2.1. Milk Collection
In the context of the larger study, when their infants were 3–5 months of age, mothers collected
a sample of their first morning milk by emptying one entire breast. The milk was then agitated,
aliquoted, and transported to the lab on ice. Samples were immediately frozen at ´20 ˝C. Frozen
milk samples were transferred to the Nutrition Obesity Research Center (NORC) on dry ice where
they were then stored at ´80 ˝C until lipids were extracted and saponified. For these analyses,
the remaining milk was shipped on dry ice to an independent laboratory where lutein, free choline,
and betaine were quantified.
2.2.2. Fatty Acid Quantification
At the UNC at Chapel Hill NORC, milk samples were analyzed for fatty acid content.
Lipids were extracted from the breast milk samples using the method of Bligh and Dyer [26].
The lower (chloroform) phase was transferred to a clean tube and evaporated to dryness under
nitrogen. The residual lipids were saponified and the fatty acids trans-methylated by sequential
1 mL addition of 4.25 % NaOH in CHCl3:MeOH (2:1, v/v) and 1N HCl in saline [27]. The samples
were mixed vigorously then centrifuged at 1500 g for 5 min. The lower phase containing the fatty
acid methyl esters was carefully transferred to a clean, dry tube and evaporated to dryness under
nitrogen. Fatty acid methyl esters were then re-suspended in 50 L undecane, and analyzed using
capillary gas chromatography (GC). Fatty acid methyl esters were analyzed by Fast GC on a Perkin
Elmer AutoSystem XL Gas Chromatograph (Shelton, CT, USA), split injection, with helium as the
carrier gas. The methyl esters were separated on a capillary column coated with 70% cyanopropyl
polysilphenylene—siloxane (10 m ˆ 0.1 mm ID-BPX70 0.2 m; SGE, Austin, TX, USA); injector
240 0C and detector 280 0C. Data were analyzed with the Perkin Elmer Totalchrom Chromatography
Software, version 6.2. Heptadecanoic acid (17:0) was added to the samples as an internal standard
to correct for recovery and quantitation. Individual fatty acids were identified by comparing their
retention with authentic standards (Nu Chek Prep, Elysian, MN, USA).
2.2.3. Choline and Betaine Quantification
Free choline and betaine were assayed in the Innis lab as detailed in Innis and Hassman [28].
Twenty µL of milk was transferred to a 1.5 mL Eppendorf tube containing 10 µL of internal standards,
deuterium labeled free choline, and vortexed. 60 µL of methanol was added and the samples were
centrifuged (14000ˆ g for 10 min). The supernatant was transferred and diluted 1/5 in an autosampler
vial containing mobile phase. Chromatographic separation was performed isocratically with 4 µL
injection of sample using an Agilent Zorbax silica column (2.1 ˆ 150 mm with 5 µm pore size)
and a mobile phase consisting of 20% 15 mmol/L ammonium formate, 0.1% formic acid in H20,
and 80% acetonitrile.
2.2.4. Lutein Quantification
Lutein content of the milk was determined using a liquid:liquid extraction method as described
by Yuhas and colleagues [29]. One mL of ethanol was added to 1 mL of a sample of human milk
and vortexed for 10 seconds. Two mL of Hexane:THF (80:20) were added to the samples and the
tubes were shaken for 15 min. The tubes were centrifuged for 15 min at 3500 rpm and the organic
layer was transferred to a new test tube. This extraction was repeated, and the organic phases were
combined. These combined organic phases were then extracted with 2 mL of ethanol: H2O (90:10) and
briefly vortexed, shaken for 10 min, and centrifuged for 5 min at 3500 rpm. The aqueous layer was
transferred to a new test tube, and the extraction was repeated with the aqueous phases combined.
The combined aqueous phases were dried under nitrogen and heat (30 ˝C). Standard solutions of
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lutein in ethanol were simultaneously carried through the extraction protocol beginning with the
addition of 1 mL water and the hexane: THF step. Then, the sample and standard extracts were
dissolved in 1 mL mobile phase (MeOH: MTBE, 85:15, v:v). Samples were vortexed and allowed
to stand until clear. Samples were transferred to amber vials for HPLC analyses, leaving behind
any insoluble material. The samples were run on an Agilent 1100 Series coupled with a Variable
Wavelength Detector. Chromatographic separation was performed using a YMC C30 carotenoid
column (5 µm, 4.6 ˆ 250 mm) and a mobile phase gradient of Methanol: MTBE (85:15) to (70:30).
Analysis was conducted with a 100 µL injection, a flow rate of 1 mL/min and detector wavelength of
445 nm. Total run time was 30 min. An external standard curve was prepared using chromatograms
of extracted standard solutions.
2.2.5. Electrophysiology Methods
In a protocol designed to test recognition memory, we recorded event-related potentials (ERP;
electroencephalogram aka EEG time-locked to stimuli presentation) and eye movements. To enable
recording, the participant was fitted with a 128-sensor Geodesic Sensor Net (GSN; Electrical Geodesic,
Inc. (EGI), Eugene, OR, USA); data were recorded from 124 sensors. Measurements were obtained
of the infant’s head to insure the proper size net was used, but also to insure proper placement of
the vertex, mastoid, and other landmark sensors. Application of the net required approximately
15 min and was well tolerated by the infants (only 2 refused to wear the net). Impedances were
checked and corrected if necessary to below 50 kΩ, and the net was connected to a NetAmps 300
(Electrical Geodesic, Inc., Eugene, OR, USA). The participant was seated on the caregiver’s lap 45 cm
from a 19” Dell monitor in the participant room (separate from the control room). A Sony DCR-HC52
camera, positioned under the monitor and time-locked to the data being acquired, recorded the
participant’s face during presentation of the pictures. Stimuli were presented by EPrime 2.0 software
(Psychology Software Tools, Inc., Sharpsburg, PA, USA). Data were digitized at 250 Hz and stored by
NetStation 4.4.2 (Electrical Geodesic, Inc., Eugene, OR, USA) on a Mac. During recording the data
were referenced to a single point at the vertex. The EGI system used a single-clock to time-lock the
presentation of the stimuli with the EEG continuous recording and the video capture.
2.2.6. Stimuli
The stimuli computer displayed pictures of wooden toys gleaned from the internet. All pictures
occupied the middle 50% of an 18 cm square on a white background with a 10 cm black border and
presented at a viewing angle of 68 degrees. All participants were shown the same picture 12 times for
1500 ms each with an inter-trial interval (ITI) of 500 ms to familiarize them with the standard picture.
The familiarization period was followed by the presentation of 100 pictures randomly ordered by
EPrime and including the standard, familiar image (70%) and 30 trial-unique novel images (30%) [30]
for 1500 ms separated by inter-stimuli intervals (500 ms) of randomly varied length (˘0 to 200 ms).
The novel images elicit reliable negative deflections (Nc) that peak approximately 600 ms after the
stimulus presentation in 6-month-olds [31]. Caregivers were instructed in techniques to redirect the
infant’s attention to the screen, if needed, to ensure the infant viewed as many pictures as possible.
Lights were off during the procedure.
2.3. Data Reduction and Analyses
2.3.1. Nutrients
Nutrient quantification data were visually examined for anomalies. To ensure that the results
were not unduly influenced by a single data point and as is the convention [32], outliers (datapoint
>3 SD above or below the mean) were removed from the dataset: one betaine (7.5 SD above the mean),
two choline (3.2 and 5.2 SD above the mean), and one DHA (5.2 SD above the mean) datapoints
were excluded.
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2.3.2. Electrophysiological Data
Recorded files were individually assessed for gaze direction based on pupillary reflection.
Videos were segmented by trial, and segments were collected into three video streams based on
condition (habituation, novel unique, familiar). The videos were opened, in turn, in iMovie ‘09
(Apple, Inc. Dolby Laboratories, San Francisco, CA, USA) and partitioned into segments each equal to
the presentation of one trial. Trial segments were individually assessed for status of the participant’s
gaze, and the status was noted on the event list. Trials in which the participant was not attending to
the stimulus were subsequently marked as “bad” in the NetStation file. This process was repeated
for each participant.
EEG waveforms were visually assessed for anomalies. Data were then subjected to a 30 Hz
lowpass filter and segmented into 1700 ms segments (200 ms before and 1500 ms after stimulus
onset). Bad channels were detected by the software using a moving average of 150 ms and a threshold
of 250 µV. Segments that included more than 13 (>10%) bad channels were rejected. Data were
baseline corrected using the mean voltage during the 200 ms preceding stimulus onset. The remaining
segments were assessed for artifacts, and when necessary, individual channels were replaced using
spherical spline interpolation. Trials were averaged within condition (novel, familiar). Across
participants, the average number of trials viewed and producing clean data were 13 for novel unique
(43%; range 10–30) and 27 for familiar (39%; range 10–66). Participants’ data were averaged together
by condition for a grand mean.
The grand mean file was visually examined, and a negative deflection window of interest was
chosen at 200 to 900 ms from stimulus onset. Visual inspection of the continuous data and review
of the literature e.g., [33] provided support for sensor clusters of interest. Data were averaged across
sensor groups as follows (see Figure 1): FrontalZ (4, 10, 11, 16, 18, 19), FrontalL (24, 27, 28, 34, 33),
FrontalR (116, 117, 122, 123, 124), CentralZ (7, 31, 55, 80, 106, REF), ParietalZ (61, 62, 67, 72, 77, 78),
and Midline (6, 11, 15, 16, 55, REF). Clusters were individually assessed for mean amplitude, peak
amplitude, and latency to peak amplitude within the 200 to 900 ms window for each condition using
NetStation 4.5.4 (Electrical Geodesic, Inc., Eugene, OR, USA). In SAS 9.2 (SAS Institute, Inc., Cary, NC,
USA), difference variables were computed for each variable from each cluster by subtracting data for
novel unique from data for familiar data.
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Figure 1. Sensor map showing the clusters used in analyses: FrontalZ (4, 10, 11, 16, 18, 19),  
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Figure 1. Sensor map showing the clusters used in analyses: Front lZ (4, 10, 11, 16, 18, 19), FrontalL
(24, 27, 28, 34, 33), FrontalR (116, 117, 122, 123, 124), CentralZ (7, 31, 55, 80, 106, REF), ParietalZ (61, 62,
67, 72, 77, 78), and Midline (6, 11, 15, 16, 55, REF).
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2.3.3. Data Analyses
Data met assumptions of normality and were analyzed in full model multivariate regressions
using the three nutrients (DHA, choline, lutein) and the interactions to predict mean amplitude, peak
amplitude, and latency to peak amplitude for each cluster using SAS 9.2. Data were then subjected
to multivariate stepwise regressions to explore potential models of import. Significant results were
followed up in reduced models. In addition, significant interactions were modeled using simple
slopes analysis, which takes a low value of a variable (one standard deviation below the mean),
the mean of a variable, and a high value of a variable (one standard deviation above the mean),
and determines whether or not the slope changes significantly with respect to the second variable.
The simple slopes procedure provides an analysis of how the variables interact by plotting the
direction and rate of change at each level of the first variable [34].
3. Results
Data were examined to ensure that assumptions were met for regression analyses. Maternal
education (as a proxy for socioeconomic status), head circumference, and infant age were tested as
potential covariates by regressing the outcome variables on to each one in turn. It was determined
that no covariates were necessary (all p > 0.05). Demographics as well as means and ranges of the
nutrient levels are in Table 1. The data were then subjected to full model multivariate regressions that
account for multiple comparisons within the analyses (Table 2). No predictors (choline, lutein, DHA,
interactions) were significant at the p < 0.05 level for mean amplitude or peak amplitude. Latency at
the central leads was predicted by choline (p < 0.01) and the lutein X choline interaction (p < 0.05).
No other instances of significance were found.
Table 1. Human milk nutrient composition determined from an aliquot of milk expressed from one
whole breast (i.e., containing fore- and hind-milk) at 3–5 mo after parturition. Infant age at sample
was computed using the n with complete nutrient data.
N Minimum Maximum Mean SD
Infant age at sample (mo) 67 3.0 5.8 3.7 0.63
Infant age at test (mo) 67 5.9 6.4 6.1 0.09
Maternal education (yrs) 67 12 20 16.4 1.63
Head circumference (6 mo; cm) 67 41.0 46.5 43.4 1.18
DHA (g/100g) 61 0.08 1.07 0.26 0.18
Free choline (umol/L) 60 23.0 326.9 158.4 68.85
Lutein (mcg/L) 62 0.0 52.6 18.4 14.85
DHA: docosahexaenoic acid; SD: standard deviation; yrs: years.
Because the sample size was small, modeling was undertaken to insure that reduced models
of significance were not overlooked. Data were entered into multivariate stepwise regressions to
account for multiple comparisons using all the predictors (choline, lutein, DHA, and interactions;
Table 3). No variables predicted mean amplitude or peak amplitude at any location cluster. Latency
at left frontal was predicted by DHA X choline interaction (p < 0.01). DHA X lutein also entered the
model at p < 0.10. The model accounted for 13.5% of the variance. Latency was also predicted at
the central leads by choline (p < 0.05), lutein (p = 0.001), and lutein X choline (p < 0.001). This model
accounted for 24% of the variance.
Significance in the model-building exercise was followed up with analyses of the reduced
models. DHA, choline, and the interaction were used to predict latency to peak amplitude (Table 4).
Latency at right frontal leads was predicted by choline (p < 0.05) and the DHA X choline interaction
showed a trend (p < 0.10). The model accounted for 11% of the variance. Left frontal latency was also
predicted by DHA (p < 0.05) and the DHA X choline interaction (p < 0.01) with 18% of the variance
explained. For latency at the central leads, both nutrients predicted (DHA, p < 0.01; choline, p < 0.05)
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as well as the interaction (DHA X choline, p < 0.001) with 21% of the variance explained. Finally,
latency along the midline was predicted by DHA X choline (p < 0.05) with a DHA trending toward
prediction (p < 0.10). This final model predicted 12% of the variance.
Table 2. Results of the full model multivariate regression predicting the difference in latency to
peak amplitude of the negative deflection seen between 200 and 900 ms when viewing novel vs.
familiar stimuli.
Lead Grouping Variable β SE t-Value p-Value Model R-Square
Frontal Z
Intercept ´23.11 144.14 ´0.16 0.87 0.04
DHA 2.19 4.51 0.49 0.63
Choline 0.58 0.74 0.78 0.44
Lutein ´1.16 6.23 ´0.18 0.86
DHA X Choline ´0.02 0.03 ´0.82 0.41
DHA X Lutein 0.02 0.07 0.24 0.81
Lutein X Choline ´0.001 0.03 ´0.02 0.98
Frontal Right
Intercept ´144.48 152.55 ´0.95 0.34 0.14
DHA 5.55 4.77 1.16 0.25
Choline 1.57 0.79 2.00 0.05 *
Lutein ´6.77 6.68 ´1.01 0.32
DHA X Choline ´0.04 0.03 ´1.69 0.10
DHA X Lutein 0.04 0.07 0.55 0.59
Lutein X Choline 0.02 0.03 0.52 0.60
Frontal Left
Intercept ´171.34 127.68 ´1.34 0.19 0.21
DHA 5.00 3.99 1.25 0.22
Choline 1.12 0.66 1.84 0.07 ˆ
Lutein 6.86 5.59 1.23 0.23
DHA X Choline ´0.04 0.02 ´1.79 0.08 ˆ
DHA X Lutein ´0.01 0.06 ´0.17 0.87
Lutein X Choline ´0.03 0.03 ´0.98 0.33
Central Z
Intercept ´307.51 135.06 ´2.28 0.03 * 0.30
DHA 3.27 4.22 0.77 0.44
Choline 1.90 0.70 2.73 0.009 **
Lutein 9.77 5.92 1.65 0.11
DHA X Choline ´0.04 0.02 ´1.72 0.09 ˆ
DHA X Lutein 0.06 0.06 0.93 0.36
Lutein X Choline ´0.06 0.03 ´2.12 0.04 *
Midline
Intercept ´125.34 133.78 ´0.94 0.35 0.13
DHA 3.02 4.18 0.72 0.47
Choline 1.01 0.69 1.46 0.15
Lutein 4.28 5.86 0.73 0.47
DHA X Choline ´0.03 0.02 ´1.25 0.22
DHA X Lutein 0.01 0.06 0.22 0.82
Lutein X Choline ´0.03 0.03 ´0.88 0.38
Parietal Z
Intercept ´46.23 188.45 ´0.25 0.81 0.08
DHA ´5.77 5.89 ´0.98 0.33
Choline ´0.01 0.97 ´0.01 0.99
Lutein 10.98 8.26 1.33 0.19
DHA X Choline 0.23 0.03 0.69 0.49
DHA X Lutein 0.26 0.09 0.29 0.77
Lutein X Choline ´0.07 0.04 ´1.59 0.12
* Significant at p < 0.05; ˆ Trending to significance at p < 0.10. DHA: docosahexaenoic acid; R-squared:
coefficient of determination; SE: standard error; ** Significant at p < 0.01.
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Table 3. Model-building results from multivariate stepwise regressions predicting the difference in
latency to peak amplitude of the negative deflection seen between 200 and 900 ms when viewing
novel vs. familiar stimuli. Variables were set to enter the equation if p < 0.15.
Lead Grouping Variable β SE F-Value p-Value Model F Model p Model R-sq
Frontal Left
Intercept 85.43 35.7 5.73 0.02 * 4.04 0.02 * 0.13
DHA X Choline ´0.02 0.007 7.88 0.007 **
DHA X Lutein 0.05 0.03 3.13 0.08 ˆ
Central Z
Intercept ´266.55 96.24 7.67 0.008 ** 5.26 0.003 ** 0.24
Choline 1.13 0.53 4.61 0.04 *
Lutein 15.66 4.46 12.35 0.0009 ***
Lutein X Choline ´0.09 0.02 14.30 0.0004 ***
*** Significant at p < 0.001; ** Significant at p < 0.01; * Significant at p < 0.05; ˆ Trending toward significance at
p < 0.1; DHA: docosahexaenoic acid; SE: standard error.
Table 4. Reduced model exploration of the significant interactions from the model-building analyses.
DHA, choline, and DHA X choline were used to predict the difference in latency to peak amplitude of
the negative deflection seen between 200 and 900 ms when viewing novel vs. familiar stimuli. Only
lead groupings showing a predictor at the p < 0.15 level in previous analyses were analyzed.
Lead Grouping Variable β SE F-Value p-Value Model F Model p Model R-sq
Frontal Right
Intercept ´229.54 127.45 ´1.80 0.08 ˆ 2.02 0.12 0.11
DHA 5.38 3.46 1.55 0.12
Choline 1.75 0.77 2.28 0.03 *
DHA X Choline ´0.04 0.02 ´1.92 0.06 ˆ
Frontal Left
Intercept ´117.69 106.95 ´1.10 0.27 3.66 0.02 * 0.18
DHA 6.81 2.90 2.35 0.02 *
Choline 1.05 0.64 1.63 0.11
DHA X Choline ´0.05 0.02 ´2.75 0.008 **
Central Z
Intercept ´312.00 117.62 ´2.65 0.01 * 4.54 0.007 ** 0.21
DHA 9.89 3.19 3.10 0.03 *
Choline 1.73 0.71 2.44 0.02 *
DHA X Choline ´0.07 0.02 ´3.44 0.001 **
Midline
Intercept ´118.24 110.56 ´1.07 0.29 2.27 0.09 ˆ 0.12
DHA 5.38 3.00 1.79 0.08 ˆ
Choline 0.94 0.67 1.40 0.17
DHA X Choline ´0.04 0.02 ´2.18 0.03 *
*** Significant at p < 0.001; ** Significant at p < 0.01; * Significant at p < 0.05; ˆ Trending toward significance at
p < 0.10; DHA: docosahexaenoic acid.
Using Preacher’s interaction utility [34], significant interactions were subjected to a simple
slopes analysis to investigate the nature of the associations. Figures 2–4 illustrate the models of the
interactions. With respect to the latency variable, difference scores that are negative are indicative of
better recognition memory. Thus, the models for latency in all three clusters indicate that recognition
memory would be the best when both DHA and choline are high.
To follow up the lutein X choline interaction found in the stepwise regressions, a reduced model
using choline, lutein, and their interaction to predict the outcome variables was run (Table 5). Brain
activity with regard to latency was predicted at left frontal by lutein (p < 0.05) and the lutein X choline
interaction (p < 0.05), which accounted for 13% of the variance in the data. At the central leads, latency
was predicted by lutein (p = 0.001), choline (p < 0.05), and the lutein X choline interaction (p < 0.001).
This model accounted for 24% Again, significant interactions were followed up using the Preacher
interaction utility [34]. Figures 5 and 6 illustrate the models for the lutein X choline interaction at
the frontal and central leads, respectively. As negative numbers indicate better recognition memory,
the model indicates that better recognition memory is seen with the combination of high choline and
high lutein.
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Figure 2. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the 
left frontal sensors. Negative numbers are indicative of better recognition. The figure depicts the 
effect of DHA at high, mean, and low levels of choline. Low choline was defined as 1 SD below the 
mean, and high choline was defined as 1 SD above the mean. Sample sizes for each group were as 
follows: low choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph 
shows the 95% CIs for the slope of the latency to peak amplitude at left frontal sensors. The slope 
outside the dotted lines is significant. CI: confidence interval; DHA: docosahexaenoic acid; SD: 
standard deviation. 
 
Figure 3. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the 
central sensors. Negative numbers are indicative of better recognition. The figure depicts the effect 
of DHA at high, mean, and low levels of choline. Low choline was defined as 1 SD below the mean, 
and high choline was defined as 1 SD above the mean. Sample sizes for each group were as follows:  
low choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph shows the 
95% CIs for the slope of the latency to peak amplitude at central sensors. The slope outside the 
dotted lines is significant CI: confidence interval; DHA: docosahexaenoic acid; SD: standard 
deviation.  
Figure 2. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the left
frontal sensors. Negative numbers are indicative of better recognition. The figure depicts the effect of
DHA at high, mean, and low levels of choline. Low choline was defined as 1 SD below the mean, and
high choline was defined as 1 SD above the mean. Sample sizes for each group were as follows: low
choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph shows the 95% CIs
for the slope of the latency to peak amplitude at left frontal sensors. The slope outside the dotted lines
is significant. CI: confidence interval; DHA: docosahexaenoic acid; SD: standard deviation.
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Figure 3. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the 
central sensors. Negative numbers are indicative of better recognition. The figure depicts the effect 
of DHA at high, mean, and low levels of choline. Low choline was defined as 1 SD below the mean, 
and high choline was defined as 1 SD above the mean. Sample sizes for each group were as follows:  
low choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph shows the 
95% CIs for the slope of the latency to peak amplitude at central sensors. The slope outside the 
dotted lines is significant CI: confidence interval; DHA: docosahexaenoic acid; SD: standard 
deviation.  
Figure 3. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the
central sensors. Negative numbers are indicative of bet rec gnition. The figur depicts the effect of
DHA at high, mean, nd low lev ls of choline. Low choline was defined as 1 SD below the mean, and
high choline was defi ed as 1 SD above the mean. Sample siz s for each group were as follows: low
choline, n = 9; m an choline, n = 4 ; and high c olin , = 10. The embedd d graph shows the 95% CIs
f r the slope of the latency to peak amplitude at central sensors. The slope outsi e the dotted lines is
significant CI: confidence interval; DHA: docosahexaenoic acid; SD: standard deviation.
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Figure 4. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the 
midline sensors. Negative numbers are indicative of better recognition. The figure depicts the effect 
of DHA at high, mean, and low levels of choline. Low choline was defined as 1 SD below the mean, 
and high choline was defined as 1 SD above the mean. Sample sizes for each group were as follows: 
low choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph shows the 
95% CIs for the slope of the latency to peak amplitude at midline sensors. The slope to the right of 
the dotted lines is significant. CI: confidence interval; DHA: docosahexaenoic acid; SD: 
standard deviation. 
Table 5. Reduced model exploration of the significant interactions from the model-building 
analyses. Lutein, choline, and lutein X choline were used to predict the difference in latency to peak 
amplitude of the negative deflection seen between 200 and 900 ms when viewing novel vs. familiar 
stimuli. 
Lead Grouping Variable  SE t-Value p-Value Model F Model p Model R-sq 
Frontal Right 
Intercept −55.56  107.18 −0.52 0.60 1.61 0.20 0.08 
Lutein −0.13 4.96 −0.03 0.97    
Choline 0.72 0.59 1.23 0.22    
Lutein X Choline −0.02 0.02 −0.59 0.56    
Frontal Left 
Intercept −64.97 91.33 −0.71 0.48 2.60 0.06 ^ 0.13 
Lutein 9.38 4.23 2.22 0.03 *    
Choline 0.38 0.50 0.77 0.45    
Lutein X Choline −0.05 0.02 −2.30 0.03 *    
Central Z 
Intercept −266.55 96.55 −2.77 0.008 ** 5.26 0.003 ** 0.24 
Lutein 15.66 4.46 3.51 0.0009 ***    
Choline 1.13 0.53 2.15 0.04 *    
Lutein X Choline −0.09 0.02 −3.78 0.0004 ***    
Midline 
Intercept −69.21 93.32 −0.74 0.46 1.71 0.18 0.09 
Lutein 7.05 4.32 1.63 0.11    
Choline 0.42 0.51 0.82 0.42    
Lutein X Choline −0.05 0.02 −1.93 0.06 ^    
*** Significant at p < 0.001; ** Significant at p < 0.01; * Significant at p < 0.05; ^ Trending toward 
significance at p < 0.10. 
Figure 4. Simple slopes model of DHA by choline interaction for latency to peak amplitude at the
midline sensors. Negative numbers are indicative of better recognition. The figure depicts the effect of
DHA at high, mean, and low levels of choline. Low choline was defined as 1 SD below the mean, and
high choline was defined as 1 SD above the mean. Sample sizes for each group were as follows: low
choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph shows the 95% CIs
for the slope of the latency to peak amplitude at midline sensors. The slope to the right of the dotted
lines is significant. CI: confidence interval; DHA: docosahexaenoic acid; SD: standard deviation.
Table 5. Reduced model explorati n of the significant interactions from the model-building analyses.
Lutein, choline, a d lutein X choline were used to predict the difference in lat y to peak amplitude
of the negative deflection s en b tween 200 and 900 ms when viewing novel vs. familiar stimuli.
Lead Grouping Variable β SE t-Value p-Value Model F Model p Model R-sq
Frontal Right
Inte cept ´55.56 107.18 ´0.52 0.60 1.61 0.20 0.08
Lutein ´0.13 4.96 ´0.03 0.97
Choline 0.72 0.59 1.23 0.22
Lutein X Choline ´0.02 0.02 ´0.59 0.56
Frontal Left
Intercept ´64.97 91.33 ´0.71 0.48 2.60 0.06 ˆ 0.13
Lutein 9.38 4.23 2.22 0.03 *
Choline 0.38 0.50 0.77 0.45
Lutein X Choline ´0.05 0.02 ´2.30 0.03 *
Central Z
Intercept ´266.55 96.55 ´2.77 0.008 ** 5.26 0.003 ** 0.24
Lutein 15.66 4.46 3.51 0.0009 ***
Choline 1.13 0.53 2.15 0.04 *
Lutei X Choline ´0.09 0.02 ´3.78 0.0 04 ***
Midline
Intercept ´69.21 93.32 ´0.74 0.46 1.71 0.18 0.09
Lutein 7.05 4.32 1.63 0.11
Choline 0.42 0.51 0.82 0.42
Lutein X Choline ´0.05 0.02 ´1.93 0.06 ˆ
*** Significant at p < 0.001; ** Significant at p < 0.01; * Significant at p < 0.05; ˆ Trending toward significance
at p < 0.10.
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Figure 5. Simple slopes model of lutein by choline interaction for latency to peak amplitude at the 
left frontal sensors. Negative numbers are indicative of better recognition. The figure depicts the 
effect of lutein at high, mean, and low levels of choline. Low choline was defined as 1 SD below the 
mean, and high choline was defined as 1 SD above the mean. Sample sizes for each group were as 
follows: low choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph 
shows the 95% CIs for the slope of the latency to peak amplitude at left frontal sensors. The slope 
outside the dotted lines is significant. CI: confidence interval; SD: standard deviation. 
 
Figure 6. Simple slopes model of lutein by choline interaction for latency to peak amplitude at the 
central sensors. Negative numbers are indicative of better recognition. The figure depicts the effect 
of lutein at high, mean, and low levels of choline. Low choline was defined as 1 SD below the mean,  
and high choline was defined as 1 SD above the mean. Sample sizes for each group were as follows: 
low choline, n = 9; mean choline, n = 41; and high choline, n = 10. The embedded graph shows the 
95% CIs for the slope of the latency to peak amplitude at central sensors. The slope outside the 
dotted lines is significant. CI: confidence interval; SD: standard deviation. 
Figure 5. Simple slopes model of lutein by choline interaction for latency to peak amplitude at the left
frontal sensors. Negative numbers ar indicative of better recognition. The figure depicts th effect of
lutein at high, mean, and low levels f choline. Low choline as defined 1 SD below the m an, and
high choline was defined as 1 SD above the mean. Sample sizes for each group were as f llows: low
choline, n = 9; mean choline, n = 41; and high choline, = 10. The emb dded grap shows the 95% CIs
for the slope of the latency to peak amplitud at left frontal sensors. The slope outsid the dotted lines
is significant. CI: confidence i terval; SD: sta dard deviation.
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4. Discussion
Milk nutrients (choline, lutein, and DHA) were investigated in relation to six-month-old infant
recognition memory as measured by an electrophysiological assessment to test the hypothesis that
these nutrients may have a synergistic effect in the brain. The results indicate that choline and
DHA function together in the brain to support memory. Specifically, high choline and high DHA
are associated with better recognition memory. In addition, the same association was found with
choline and lutein. Importantly, these relations were evident only in the latency to peak amplitude
measure and were most prominent in the central area of the scalp, but also were seen in the frontal
areas and down the midline.
Latency to peak amplitude is interpreted as a measure of sustained attention [35–39].
Importantly, the difference between the latency to peak amplitude when viewing novel pictures and
when viewing familiar pictures is assumed to be indicative of recognition memory. When infants have
been exposed repeatedly to an image (familiar), they no longer have a need to process any information
about the familiar image. Thus, they do not attend to it. If there is a large difference between
the amplitudes when viewing novel and familiar, we assume it is because the infants recognize the
familiar picture and do not process it, whereas they do not have a memory of the novel picture and
as such, they attend to it and process it. In this study, trial unique pictures (30 unique pictures seen
only once each) were used for the novel condition [30]. Traditionally, the oddball paradigm consists
of one novel stimulus occurring repeatedly, but with less frequency than the familiar stimulus [40].
In previous research [30], we showed that the infants also stop processing a repeatedly presented
novel picture toward the end of the session. This finding provided more support for the idea that as
the image becomes familiar to the infant, processing and attention wane, and this change is evident
in the latency to peak amplitude in the Nc (negative component). Thus, the difference between the
latency to peak data for novel and familiar stimuli, in this paradigm, is indicative of whether or
not the stimulus on the screen warranted attention and processing. From this difference, we infer
recognition memory.
In this sample, recognition memory was better when DHA and choline were both high. Some
researchers, but not all, who have studied the effects of DHA on cognition have observed positive
results [41–44]. The effects of choline on cognition have been shown repeatedly in animal models [45].
The relation between choline and human cognition has been more elusive with one group finding
effects of choline in an adult population [7], but in children, no effects of concurrent choline on
cognition have been found [3] and relations between early cognition and maternal choline have
been mixed [2,4–6]. To our knowledge, the synergistic effects of DHA and choline have not been
studied previously.
It has been suggested that DHA and lutein are transported to the brain most readily
by high-density lipoproteins [23], which are rich in phosphatidylcholine. Phosphatidylcholine
(PC) is a phospholipid that serves as a structural component in the greater percentage of cells
(50–70% of cells) as it comprises the cell membrane and influences membrane fluidity with
downstream effects on signal transduction. Synthesis of PC through the hepatic de novo pathway
by phosphatidylethanolamine N-methyltransferase (PEMT), using S-adenosylmethionine (SAM) as
substrate, results in PC that is enriched in long-chain polyunsaturated fatty acids such as DHA.
Importantly, PC serves an active role in mediating hepatic export of fatty acids (e.g., DHA).
Erythrocyte PC-DHA is integral to our consideration of a potential mechanism behind our results
as the increase of PC-DHA has been shown to be related to an increase in DHA in brain tissue in
an animal model [46]. Thus choline is important in exporting hepatic DHA to extra-hepatic tissues
(e.g., brain). Indeed, it has been demonstrated in healthy adult women that providing supplemental
choline in the diet can increase the erythrocyte PC-DHA proportion possibly via increased hepatic PC
synthesis by PEMT and its export [47]. Thus, it is reasonable to postulate that when both DHA and
choline intakes are higher, more hepatic DHA is available for extra-hepatic tissues such as brain via
PEMT-PC mediated export, and subsequently, DHA is likely increased in the brain relative to when
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the two nutrients are at lower levels. In the brain, the sequence of events when the nutrients are
higher would mean that information could flow more readily across the synapses, thereby improving
information processing, as seen in this study, and possibly, improving the storage of that information
into memory (not assessed in this study). However, it is important to note that the interactions found
to be significant in this study were with free choline not phosphatidylcholine.
Another possibility for the synergistic activity of DHA and choline could be an increase in
synaptogenesis [48]. Wurtman posits that a combination of DHA, choline, and uridine is integral
to synaptogenesis, and has shown in an animal model that the proteins needed for the formation
of a synapse [49] are indeed increased as is dendritic complexity [50] when these compounds are
supplemented. In addition, this research group has shown that the administration of DHA, choline,
and uridine resulted in cognitive enhancement in the animals as evidenced by improved scores on
tasks such as the Morris Water Maze [51]. Importantly, uridine is not bioavailable in foods, except
human milk. Early on in human life, there is a natural proliferation of synapses [52] followed by
selective retraction in a “what you don’t use, you lose” scenario. DHA, choline, and bioactive uridine
(uridine monophosphate) in human milk may work to insure that proliferation.
Even though in this study maternal diet was not assessed, the nutrient content of the milk may
be considered an approximation, or at a minimum, a hint at general maternal diet [53,54]. Mothers
with high choline and high DHA in their milk were either eating a diet rich in these nutrients
or their precursors, or they were consuming quality supplements during the breastfeeding period.
If we assume that maternal diet was similar in the prenatal months, the prenatal diet of mothers with
subsequent high choline and DHA milk content most likely would have resulted in an intrauterine
environment that included optimal amounts of DHA and choline. Evidence in animal models [55–58]
and some in studies with humans [4,44] would certainly indicate an improvement in neural structures
when the fetal brain develops in a milieu that includes high levels of DHA, choline, and other
nutrients such as lutein.
The choline and lutein interaction was also significant for latency to peak amplitude: when
lutein and choline were high, performance was better. Lutein has been shown to be important at
the eye [17,59], but has been studied mostly in elderly as it is integral to the prevention of macular
degeneration. However, the level of lutein in the macula can be used as a proxy for brain tissue levels
and in fact, lutein has been related to cognitive function in the elderly [19]. During development,
lutein accretion in the macula may improve visual acuity in the infant. If high milk lutein results in
visual acuity that develops more rapidly than in infants consuming lower lutein milk, the former may
have a cognitive advantage. Seeing clearly sooner could enable infants to learn more quickly.
In addition, it is possible lutein provides as yet undiscovered support in the brain. Using
metabolomics, Lieblein-Boff et al., have shown that lutein not only is concentrated in the neural
substrates that underlie cognition (i.e., occipital, temporal, and frontal lobes), but also is correlated
with fatty acids and phospholipids in the brain [60]. Carmichael and colleagues found that lutein
intake is related to a lower risk of neural tube disorders [61], a risk previously thought to be
attributable to low levels of folate and choline. Certainly, lutein appears in natural foods alongside
choline and DHA, which also suggests co-activity. The connection between choline and lutein
warrants further investigation as does the contribution of lutein itself to brain function.
Future research will also need to include investigations of maternal diet, a limitation in the work
reported here. Knowing whether the diets of these mothers with high milk DHA and choline included
preformed nutrients, precursor nutrients, supplements, or a combination would provide clues as
to the pathways involved in the optimization of neural substrate development and/or neuronal
function. Interestingly, the results of the Carmichael study [61] showed a stronger association
between a lower risk of neural tube defects and higher lutein when the mothers were not taking
supplements relative to when supplements were consumed. This intriguing finding implies that
supplement intake may affect the bioavailability of other natural nutrients.
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Just as we cannot be certain about prenatal effects, another limitation of this work is the lack of
concurrent cognition and milk nutrient measures. We cannot draw any firm conclusions about how
day-to-day nutrition is affecting brain activity because the nutrients were measured in one sample
when the infants were three to four months old (mo) and recognition memory was measured when
they were six months of age. With the exception of total choline, which reportedly is maintained
at a relatively steady level in milk across the first year of life [62], nutrient levels in human milk
change across the first weeks of life as the milk changes from colostrum (0–3 days) to transitional
milk (5 days to 2 weeks) to mature milk (4–6 weeks to end of lactation). Indeed, DHA decreases in
the first 12 weeks, but then is present at a constant level to at least six months of age [63]. Thus, the
level of nutrients in milk at 3.5 mo would most likely be similar at six months if the maternal diet
remained constant. Nonetheless, we have no direct evidence. Similarly, we have no evidence that
the relations seen were a direct effect of improved recognition memory as opposed to a secondary
effect of improved visual acuity. The analyses reported here are secondary analyses of data from a
larger study. Future work will be specifically designed to clarify whether the nutrients we measured
were acting as a proxy for prenatal or concurrent nutrients or if the effect we report is the result of
early nutrition affecting later cognitive abilities. Future studies should also be designed to assess
visual acuity.
5. Conclusions
The finding that choline and DHA as well as choline and lutein are working together in support
of infant brain development and subsequent cognitive development is important. Since both lines of
inquiry (choline and DHA in isolation) have been fraught with mixed results, a different approach
is warranted. Studying the nutrients together may yield more consistent results, but also, it may
provide better substantiation of the mechanism behind nutritional support of brain development.
Follow-up of this cohort is underway to determine if the difference in memory abilities was merely a
short-lived delay or if the effects related to differential nutrient intake was longer lasting.
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